Glucocorticoid-Induced Osteoporosis

被引:236
|
作者
Buckley, Lenore [1 ]
Humphrey, Mary B. [2 ]
机构
[1] Yale Sch Med, 300 Cedar St,POB 208831, New Haven, CT 06520 USA
[2] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA
来源
NEW ENGLAND JOURNAL OF MEDICINE | 2018年 / 379卷 / 26期
关键词
BONE-MINERAL DENSITY; DOUBLE-BLIND; RHEUMATOID-ARTHRITIS; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURES; ORAL CORTICOSTEROIDS; BREAST-CANCER; PREVENTION; RISK; PLACEBO;
D O I
10.1056/NEJMcp1800214
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
For the past month, a 75-year-old woman with polymyalgia rheumatica has received prednisone at a dose of 20 mg daily. The treatment plan is to try to taper the dose to 5 mg daily within 6 months. Given typical durations of treatment, the expectation is that she will continue to receive prednisone for 2 years. She is otherwise healthy and has no personal or family history of fracture. She does not smoke or drink alcohol. Her height is 168 cm, and she weighs 68 kg. Her serum 25-hydroxyvitamin D level is 30 ng per milliliter (74 nmol per liter). Her bone mineral density T score is -1.2 at the femoral neck. What would you advise to prevent glucocorticoid-induced osteoporosis and fracture?
引用
收藏
页码:2547 / 2556
页数:10
相关论文
共 50 条
  • [31] Glucocorticoid-induced osteoporosis
    Adachi, J. D.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 239 - 240
  • [32] Glucocorticoid-induced osteoporosis
    Papapoulos, SE
    OSTEOPOROSIS 1996, 1996, 1118 : 359 - 367
  • [33] Management of Glucocorticoid-Induced Osteoporosis
    Rizzoli, R.
    Adachi, J. D.
    Cooper, C.
    Dere, W.
    Devogelaer, J. P.
    Diez-Perez, A.
    Kanis, J. A.
    Laslop, A.
    Mitlak, B.
    Papapoulos, S.
    Ralston, S.
    Reiter, S.
    Werhya, G.
    Reginster, J. Y.
    CALCIFIED TISSUE INTERNATIONAL, 2012, 91 (04) : 225 - 243
  • [34] MANAGING GLUCOCORTICOID-INDUCED OSTEOPOROSIS
    Popa, F. L.
    Ristea, R. P.
    Stanciu, M.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2024, 36 : S436 - S436
  • [35] Glucocorticoid-induced osteoporosis in men
    van Staa, TP
    OSTEOPOROSIS INTERNATIONAL, 2005, 16 (05) : S11 - S11
  • [36] Overview of glucocorticoid-induced osteoporosis
    Paget, SA
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 1999, 5 (05) : S1 - S2
  • [37] Treatment of glucocorticoid-induced osteoporosis
    Mazziotti, Gherardo
    Giustina, Andrea
    Canalis, Ernesto
    Bilezikian, John P.
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2009, 1 (01) : 27 - 34
  • [38] Advances in Glucocorticoid-Induced Osteoporosis
    Debby den Uyl
    Irene E. M. Bultink
    Willem F. Lems
    Current Rheumatology Reports, 2011, 13 : 233 - 240
  • [39] Pathophysiology of glucocorticoid-induced osteoporosis
    Schnitzer, TJ
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 1999, 5 (05) : S10 - S15
  • [40] Densitometry in glucocorticoid-induced osteoporosis
    Maricic, M
    Gluck, O
    JOURNAL OF CLINICAL DENSITOMETRY, 2004, 7 (04) : 359 - 363